Effect of nicotine 6 mg gum on urges to smoke, a randomized clinical trial
Tóm tắt
Ability to manage urges to smoke is fundamental to maximizing the chances of success in smoking cessation. Previous studies have linked a higher dose of nicotine in nicotine replacement therapy to a higher success rate for smoking cessation. Thus, this study was performed to compare relief of urges to smoke, up until 5 h following treatment with a new 6 mg nicotine gum versus currently marketed 4 mg nicotine gum. This was a randomized crossover clinical study. Following 12 h of abstinence from smoking, either one 6 mg or one 4 mg nicotine gum was given to 240 healthy adult smokers. Thereafter, urges to smoke were scored on a 100 mm Visual Analogue Scale repeatedly over 5 h. The reductions in urges to smoke over the first 1 and 3 h after administration were statistically significantly greater with 6 mg than 4 mg gum, (p < 0.005). A 50% reduction in perceived urges to smoke was reached in 9.4 min with 6 mg gum compared to 16.2 min with 4 mg gum (median values). The median duration of a 50% or more reduction in VAS urges to smoke score was 111 min with the 6 mg gum, versus 74 min for the 4 mg gum. This study provides evidence that the 6 mg nicotine gum provided a greater reduction, faster and longer relief of urges to smoke than the 4 mg nicotine gum. EudraCT Number: 2010–023268-42. Study was first entered in EudraCT 2011-02-23.
Tài liệu tham khảo
Piasecki TM. Relapse to smoking. Clin Psychol Rev. 2006;26(2):196–215.
Swan GE, Ward MM, Jack LM. Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav. 1996;21(4):481–90.
Shiffman S. Refining models of dependence: variations across persons and situations. Br J Addict. 1991;86(5):611–5.
Shiffman S, et al. Individual differences in the context of smoking lapse episodes. Addict Behav. 1997;22(6):797–811.
Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006;74(6):1153–61.
McCarthy DE, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction. 2008;103(9):1521–33.
Piper ME, et al. Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol. 2008;117(1):94–105.
Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83(4):531–41.
Fiore, M., Jaén, C.R., Benowitz, N.L., Curry, S.J., Dorfman, S.F., Henderson, P.N., Treating Tobacco Use and Dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respiratory care, 2008. 53 9: p. 1217–22.
Hartmann-Boyce J, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5:CD000146.
Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
Tonnesen P, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European anti-smoking evaluation. European Respiratory Society. Eur Respir J. 1999;13(2):238–46.
Balmford J, et al. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC four-country survey. Nicotine Tob Res. 2011;13(2):94–102.
Cummings KM, Hyland A. Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health. 2005;26:583–99.
Hansson A, Rasmussen T, Kraiczi H. Single-dose and multiple-dose pharmacokinetics of nicotine 6 mg gum. Nicotine Tob Res. 2017;19(4):477–83.
Wadgave U, Nagesh L. Nicotine replacement therapy: an overview. Int J Health Sci (Qassim). 2016;10(3):425–35.
Franken IH, et al. Selective cognitive processing of drug cues in heroin dependence. J Psychopharmacol. 2000;14(4):395–400.
Singleton EG, Anderson LM, Heishman SJ. Reliability and validity of the tobacco craving questionnaire and validation of a craving-induction procedure using multiple measures of craving and mood. Addiction. 2003;98(11):1537–46.
Hansson A, et al. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open. 2012;2((5)).
Mogg K, Bradley BP. Selective processing of smoking-related cues in smokers: manipulation of deprivation level and comparison of three measures of processing bias. J Psychopharmacol. 2002;16(4):385–92.
Niaura R, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005;100(11):1720–30.
Thewissen R, et al. Renewal of cue-elicited urge to smoke: implications for cue exposure treatment. Behav Res Ther. 2006;44(10):1441–9.
Thewissen R, et al. Context-dependency of cue-elicited urge to smoke. Addiction. 2005;100(3):387–96.
Wewers ME, Rachfal C, Ahijevych K. A psychometric evaluation of a visual analogue scale of craving for cigarettes. West J Nurs Res. 1990;12(5):672–81.
West R, Ussher M. Is the ten-item questionnaire of smoking urges (QSU-brief) more sensitive to abstinence than shorter craving measures? Psychopharmacology. 2010;208(3):427–32.
Zinser MC, et al. Manipulating smoking motivation: impact on an electrophysiological index of approach motivation. J Abnorm Psychol. 1999;108(2):240–54.
Glover E, Sachs DPL, Stitzer ML, Rennard SI, Wadland WC, Pomerleau OF, Nowak RT, Daughton DM, Glover PN, Hughes JR, Gross J. Smoking Cessation in Highly Dependent Smokers with 4 mg Nicotine Polacrilex. Am J Health Behav. 1996;20(5):319–32.
Herrera N, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest. 1995;108(2):447–51.
Tonnesen P, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav. 1988;13(1):17–27.
Garvey AJ, et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res. 2000;2(1):53–63.